Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research (IOR) of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI)

NEXT STORY
Immune Health Supplements Market Exhibit 7.4% CAGR and Reach USD 29.40 Billion 2027; Rapid Changes in Lifestyles to Bolster Growth, says Fortune Business Insights™
PREV STORY
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April

Oslo, Norway, 19 April 2017 - Targovax ASA (OSE: TRVX), a clinical stage company ...

author_avatar
NASDAQ Market News

CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs

SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News

Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

 --Preclinical Studies Demonstrate Activity of CPI-444 Both Alone and in Combination with Anti-PD-1 and Anti-PD-L1 ...

author_avatar
NASDAQ Market News